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Abstract Phage lambda lysozyme (VL) is structurally related to
other known lysozymes but its mechanism of action is different
from the classical lysozyme mechanism, acting as a transglyco-
sidase rather than a hydrolase. As two conformations have been
revealed by the crystal structure, we investigated the effect of
mutating and modifying a histidine located near to or far from
the active site in the respective closed and open conformations.
Whereas its asparagine mutation has little or no effect on
activity, its N-carbethoxylation inactivates the enzyme. This
provide further evidence for the involvement of the closed
conformation and for the need of conformational mobility in
VL function.
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1. Introduction
Obviously, proteins cannot be reduced to rigid and orga-
nized functional structures. Flexibility and conformational
changes often play critical roles for protein function [1]. Es-
pecially in the case of enzymatic catalysis, conformational
mobility can help an enzyme to adapt its active site along
the reaction pathway such that all the steps, from substrate
binding to product release, are optimized. A great variety of
internal motions occurring on di¡erent time scales and ampli-
tudes have been described and some of them have been shown
to be involved in the mechanism of action of enzymes. Large
conformational changes have been reported upon substrate
binding, particularly the hinge-bending motion often observed
for enzymes made of two domains. More subtle conforma-
tional events can also accompany the di¡erent steps of the
catalytic cycle or the mechanism of allosteric regulation.
In this study, we investigate the hypothesis of a functional
motion possibly occurring for the lambda lysozyme (VL). VL
is implicated in the degradation of the peptidoglycan of Es-
cherichia coli in the ¢nal stage of the infection cycle. This 158
residue protein has been puri¢ed and characterized [2^5]. Its
three-dimensional structure has been determined recently [6]
and has con¢rmed the prediction that VL is evolutionarily
related to other viral lysozymes even though the sequences
are almost unrelated, VL sharing only 18% sequence identity
with the well-known lysozyme of phage T4 (T4L) [7]. The
enzyme is made up of two domains between which the active
site cleft of the enzyme is formed. Interestingly, the crystallo-
graphic data revealed two distinct conformational states for
VL but, instead of a hinge-bending motion between the two
domains as observed for T4L [8^10], the change comes from a
peptide segment in the C-terminal domain of the enzyme that
either opens or closes the active site cleft. This observation is
probably not a crystallization artifact as conformational het-
erogeneity in solution has also been described from 19F NMR
for a derivative of VL labelled with tri£uoromethionine [11].
The VL structure also con¢rmed the position of Glu-19, the
essential glutamic acid common to all known lysozymes, in
the active site cleft whereas there is apparently no second
catalytic residue such as Asp-20 for T4L or Asp-52 for hen
egg white lysozyme (HEWL). Moreover, the mechanism of VL
has been shown to be di¡erent from that of the intensively
investigated HEWL and T4L (for reviews on lysozymes, see
[12^15]) : VL is not a hydrolase but a transglycosidase, the
hydroxyl function on the C6 of the muramic acid of the mur-
opeptide replaces water as a nucleophile in the reaction with
the oxycarbocation intermediate; the product is a 1,6-anhy-
dro-muropeptide [16^18]. The same 1,6-anhydro-muropeptide
is formed by the soluble lytic transglycosidase (Slt70) of E.
coli [19], a 70 kDa enzyme containing a catalytic domain
showing signi¢cant structural similarity with the T4 lysozyme
despite the lack of detectable sequence similarity [20]. Inter-
estingly, the ‘catalytic’ aspartate is also absent in Slt70 [21], a
di¡erence shared by VL that could be related to a di¡erent
mechanism of cleavage of the L-1,4-glycosidic bond. Never-
theless, this aspartate is also lacking in several other lyso-
zymes with hydrolase activity [15] and the origin of the change
in mechanism between the VL and Slt70 transglycosidases and
the other lysozymes remains unexplained.
To test the hypothesis of a functional motion, we focused
our attention on a histidine residue (His-137) located at a
surface position distant from the active site cleft in the open
conformation and which is found in a rather buried environ-
ment in the vicinity of the active site Glu-19 in the closed
conformation. The e¡ects of chemical modi¢cation with di-
ethyl pyrocarbonate (DEPC) and of mutation to asparagine
were analyzed. The two other histidines of VL (His-31 and
His-48) were also mutated in order to unambiguously address
the chemical modi¢cation of His-137. Whereas the H31N-
H137N mutant behaves essentially as the wild type enzyme,
the N-carbethoxylation of His-137 by DEPC appears to in-
activate the wild type enzyme. These results support the hy-
pothesis that the conformational mobility observed in the
crystal structures of VL is an intrinsic functional property of
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VL in solution. Implications for the mechanism of action are
discussed.
2. Materials and methods
2.1. Materials
Restriction enzymes were purchased from Boehringer, Eurogentec
(Belgium) and Gibco BRL. Calf intestinal alkaline phosphatase, T4
DNA ligase and T4 polynucleotide kinase were purchased from Gibco
BRL. All other reagents were of analytical grade. Oligonucleotides
were purchased from Eurogentec:
b (I) 5P-ATAACCATCATTTCTGG-3P
b (II) 5P-GCGAGGGTTATCGGAGT-3P
b (III) 5P-CAGAAAACTAGAAATAATGGTTATGACGT-
3P
b (IV) 5P-CATAACCATTATTTCTAGTTTTCTGACGT-3P
b (V) 5P-TCACTGCCGGGCGCTGGTTATGGTCAGTTC-
GAGAATAAGGCTGAC-3P
b (VI) 5P-TGCAGGGTCGACGGATCCTCGGGAATTCA-
T-3P
2.2. Genetic engineering methods
The lambda R gene encoding the lysozyme has been cloned with a
synthetic ribosome binding site in a pPlc236 vector [22] to give
pLJ0516 where it is expressed at a high level from the PL promoter
under the control of the thermolabile CI857 repressor [23].
The H31D and H48N mutants were constructed by oligonucleotide-
directed mutagenesis following the phosphorothioate procedure [24]
with primers I and II respectively.
The H31N and the H31N-H137N mutants were made by cassette
mutagenesis. For the H31N mutation, we took advantage of two
closely spaced AatII sites £anking the H31 codon. The plasmid
pLJ0516 was digested by AatII to excise a 31 bp fragment. The aga-
rose-puri¢ed large fragment was dephosphorylated with calf intestinal
alkaline phosphatase (CIAP). A mixture of two complementary oli-
gonucleotides, III and IV, bearing the required mutations was phos-
phorylated with T4 polynucleotide kinase. After enzyme inactivation
at 70‡C and hybridization, the synthetic duplex was ligated with the
large fragment by T4 DNA ligase. To select the plasmid (pPS07)
bearing the insert in the correct orientation, a silent mutation intro-
ducing a stop codon in the incorrect orientation was introduced.
Upon induction on small cultures, lysozyme was detected by SDS-
PAGE electrophoresis.
For unknown reasons, the H137N mutation could not be made by
oligonucleotide-directed extension mutagenesis. To overcome the
problem, we took advantage of the existence of a NciI site in the R
gene near the H137 codon. The plasmid encoding the double mutant
was reconstructed in a three fragment ligation: (1) a large fragment
(4.3 kbp) was derived from BglII and SalII digestion of pPS08, a
plasmid identical to pPS07 except that the HindIII site upstream of
the R gene is replaced by BglII; (2) a 395 bp fragment was derived
from NciI restriction of the small fragment obtained after BglII-SalI
restriction; (3) a 125 bp fragment, which introduces the H137N mu-
tation and removes the SmaI and NciI sites of the polylinker, was
generated by PCR with primers V and VI and restricted with SalI and
NciI. The 395 and 125 bp fragments are phosphorylated with T4
kinase. After ligation and transformation, the expected plasmid,
pPS10, is found by restriction with Bgl II, Sal I and SmaI.
2.3. Puri¢cation and characterization of the enzymes
The wild type and mutant VL were expressed in E. coli strain
M5219 harboring the corresponding plasmids following a protocol
described previously that strongly reduces the heat shock-induced
proteolysis in vivo [25]. The wild type VL and the H31D, H31N-
H137N mutants were puri¢ed as described previously [23]. The
H48N mutant enzyme was found as inclusion bodies and was rena-
tured before puri¢cation as described previously [7].
Activities and stabilities to reversible thermal denaturation were
measured as described previously [23,26]. Activity-pH pro¢les were
obtained at an ionic strength of 20 mM. Reversible denaturations
were followed in 100 mM phosphate bu¡er, pH 7.0.
Chemical modi¢cation of the histidines was performed with DEPC
[27]. Solutions of wild type or mutant VL of known concentration
were prepared by measuring their A280 and taking an extinction co-
e⁄cient of 30 000 M31 cm31 [26]. The chemical modi¢cation was
followed by measuring the absorbance change in the far UV and
the e¡ect on activity. 20 Wl of a 0.4 M solution of DEPC in acetoni-
trile was added to 2 ml of 1035 M solutions of the enzymes in 50 mM
phosphate or MES bu¡er at pH 6.0. The absorbance was followed at
242 nm. 16 Wl of 0.4 M DEPC in acetonitrile was added to 1 ml of
6 U1037 M enzyme in 50 mM phosphate bu¡er at pH 6.0. Aliquots
of this solution were taken to measure the residual activity as a func-
tion of time. For the H31N-H137N mutant, measurements were per-
formed in bis-Tris (pH = 7.5, 7.0 and 6.5) or MES (pH = 6.5, 6.0 or
5.5) bu¡ers. The reversibility of the modi¢cation was measured by
adding 50 Wl of hydroxylamine at a ¢nal concentration of 0.1 M to
an enzyme solution whose residual activity in the course of inhibition
had reached approximately 5%. The evolution of the lytic activity was
then followed by measurements on aliquots as a function of time.
3. Results
3.1. Enzymatic activity and stability of wild type and mutants
VL
The lytic activity of these enzymes on EDTA-sensitized E.
coli cells was measured as a function of pH at an ionic
strength of 20 mM. As shown in Fig. 1, the maximal activities
of the H31D and the H31N-H137N mutants were very similar
to that of the wild type enzyme. The H48N mutation reduced
the maximal activity to 3% of the wild type.
The stability of mutant enzymes to reversible denaturation
was measured at pH 7.0 by following the £uorescence of the
protein as a function of temperature. Sigmoidal curves were
obtained for all the mutants. An identical loss of £uorescence
intensity (50%) was observed upon unfolding of wild type,
H31D and H31N-H137N enzymes. This information, together
with the catalytic activity measurements, indicates that these
two mutant enzymes are properly folded. A lower £uorescence
decrease was observed upon unfolding of the H48N mutant
Fig. 1. pH dependence of the lytic activity observed for wild type
(squares), H31D (triangles), H31N-H137N (circles) and H48N (dia-
monds) lysozymes. Activities were obtained by measuring the lysis
rate of suspensions of EDTA-sensitized E. coli cells (decrease of the
suspension turbidity at 570 nm). Rates are expressed in relative
units; 100 units correspond to the wild type maximum activity ob-
served at pH 7.
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(40%). The Tm and vHD(Tm) values were extracted from the
£uorescence curves and are given in Table 1 together with the
free energy of denaturation calculated at 25‡C by the method
described previously [26].
3.2. Chemical modi¢cation with DEPC
On incubation with 0.4 mM DEPC at pH 6.0, the wild type
VL loses its activity with a half-time of about 7 min. The
inactivation may result from the chemical modi¢cation of
one or several histidines as DEPC is a reagent designed to
modify these residues selectively [27]. N-Carbethoxylation of a
histidine is accompanied by a spectral change in the far UV:
the absorbance at 242 nm increases (vO= 3200 M31 cm31).
However, this reagent is not totally speci¢c for histidines:
lysines, tyrosines and cysteines are susceptible to modi¢cation
giving products of high, medium or very low stability [28]. O-
Carbethoxylation of tyrosine is detectable by its e¡ect on
absorbance at 278 nm (vO=31310 M31 cm31) [29]. The carb-
ethoxylation of histidine can be reversed by incubation with
20 mM hydroxylamine while that of tyrosines or lysines is not.
In order to determine the origin of the DEPC inactivation
of VL, we have run chemical modi¢cation experiments on
several mutants, and followed the spectral changes and the
e¡ects on activities.
The H31N-H137N mutant contains only one remaining
histidine (His-48). On incubation of this enzyme with 0.4^4
mM DEPC, an exponential decrease in activity was observed.
The rate constant of the reaction was determined by ¢tting the
residual activity Ar with the following equation:
Ar  Ai e3k1t 1
A second order rate constant was obtained by dividing k1 by
the DEPC concentration:
k1  k2 DEPC 2
The rate constants of inactivation were measured at several
pHs. They increased exponentially from 0.04 M31 s31 at pH
5.5 to 2.3 M31 s31 at pH 7.5. As no levelling o¡ was observed
at pH 7.5 (data not shown), the pKa of the modi¢ed residue
must be above 7.5. The inactivation could not be reversed by
incubation with 100 mM NH2OH. When the modi¢cation was
followed at 242 nm at pH 7 and 8‡C no absorbance increase
was detected (the low temperature was used to avoid a slow
precipitation of the enzyme). All these results show that His-
48 cannot be modi¢ed; the inactivation is most probably a
consequence of the modi¢cation of the lysine side chains or of
the K-amino function.
The e¡ect of H137 modi¢cation was analyzed by incubation
of the H31D mutant at pH 6.0 with DEPC: an absorbance
increase (vAobs) was observed at 242 nm as a function of
time; it can be ¢tted with the following equation:
vAobs  vAW13e3k1t 3
which is used with Eq. 2 to determine the second order rate
constant: k2 = 2.3 M31 s31 at pH 6. Dividing the vA by the
enzyme concentration gives a vO242 = 3250 M31 cm31. This
value is indicative of the modi¢cation of one histidine. As
His-48 is not modi¢ed, this re£ects the modi¢cation of
H137. The e¡ect of this modi¢cation on activity was also
determined: the enzyme was inactivated with a rate constant
k2 = 3.8 þ 0.5 M31 s31. The inactivation can be partially re-
versed (40%) by incubation with NH2OH. This lack of full
reactivation comes most probably from the combination of
the rapid reversible modi¢cation of His-137 and the slow irre-
versible modi¢cation described for the H31N-H137N mutant.
The e¡ect of H31 modi¢cation was estimated by analysis of
the modi¢cation of the wild type VL at pH 6.0. It is known
that H137 is modi¢ed but not H48. If H31 is also modi¢ed,
the absorbance increase at 242 nm in the presence of DEPC
should follow a bi-exponential curve according to the follow-
ing equation:
vAobs  vAW130:5 e3k1at  0:5 e3k1bt 4
where k1a and k1b are the ¢rst order rate constants of mod-
i¢cation of His-31 and His-137. Second order rate constants
are obtained by dividing them by the DEPC concentration
(Eq. 2). For ¢tting the observed absorbance change to Eq.
4, k2:H137 is ¢xed at 2.3 M31 s31. From the other parameters
obtained in the ¢tting and the known enzyme concentration,
the following values are obtained: k2:H31 = 1.26 M31 s31 and
vO242 = 5400 M31 cm31, i.e. 2700 M31 cm31 per histidine. No
decrease in absorbance at 278 nm is observed indicating that
tyrosines are not modi¢ed under these conditions. The wild
type enzyme is also inactivated by DEPC; the activity decays
according to a single exponential from which a second order
rate constant can be obtained: k2 = 3.9 þ 0.7 M31 s31. This
value is close to that observed with the H31D mutant.
From these results, it appears that H31 can be modi¢ed but
that its modi¢cation does not inactivate the enzyme. Again
the inactivation can be partially (40%) reversed by hydroxyl-
amine treatment.
4. Discussion
In the recently determined structure of VL [6] each histidine
of VL appears to be situated in a di¡erent environment (Fig.
2). His-31 is completely solvent exposed and located in a turn
relatively far (V12 Aî ) from the essential Glu-19 in the active
site cleft. Its environment is identical in both enzyme confor-
mations. Therefore, it is not surprising that its modi¢cation
and mutation does not signi¢cantly a¡ect the enzyme activity.
The rate constant of modi¢cation is consistent with literature
values that are in the range of 0.4^12.5 M31 s31 around pH 7
for accessible histidines residues [27]. On the surface of VL,
His-31 is close to the negatively charged Asp-22 (V5 Aî ).
Therefore, the e¡ect of the H31D mutation on the protein
stability is consistent with a weak destabilization upon intro-
Table 1
Thermodynamic parameters for the reversible thermal denaturation
of wild type and mutant lysozymes
Enzyme Tam(‡C) vHD(Tm)
b
(kcal/mol)
vGD(25)c
(kcal/mol)
VLwt 52.3 113.3 7.1
VLH31D 46.1 99.8 5.5
VLH31NÿH137N 54.3 107 8.9
VLH48N 30.1 60.8 2.1
aTemperature of half denaturation (experimental).
bEnthalpy of denaturation at Tm (experimental).
cFree energy of denaturation at 25‡C (calculated as described in
[30]).
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duction of an additional negative charge. Moreover, the pH
dependence of the di¡erence in free energy of unfolding be-
tween VLwt and VLH31D revealed that the pKa of His-31 is
slightly higher than normal (V7.2, data not shown), indicat-
ing a stabilizing interaction between His-31 and Asp-22.
The L domain of the enzyme contains His-48, located in a
coiled structure just after a L-strand. As for His-31, the envi-
ronment of His-48 is identical in both enzyme conformations.
This residue is completely buried in a hydrophobic pocket and
its pKa has been shown to be very low (92.7 [30]). Hence, it is
not surprising that His-48 cannot be modi¢ed by DEPC. The
reduced activity of the H48N mutant is most probably due to
a perturbation a¡ecting the structure of the L domain as sug-
gested by the loss of around 5 kcal/mol calculated for the His-
48 mutation (Table 1).
As shown in Fig. 2, the large conformational change re-
vealed by the crystallographic study [6] involves residue 137.
In the crystal lattice, the enzyme was found in two distinct
states, an open conformation and a closed one. In the open
structure, His-137 is part of the amino-terminal end of the last
K-helix, well accessible to the solvent and relatively far away
from the active site cleft (about 18 Aî from the essential Glu-
19). The shortest possible distance between an imidazole ni-
trogen and a neighboring atom is 5.1 Aî (between NN and
ONof Asp-140). In this environment, His-137 should react
easily with DEPC without a¡ecting the enzymatic activity.
In the closed structure, this helix is partially disrupted and
residues 128^138 have moved towards the active site cleft,
the distance between Glu-19 and His-137 being reduced to
about 9 Aî . The imidazole ring is partially buried and is poorly
accessible for N-carbethoxylation by DEPC: His-48-Ne is in-
volved in a hydrogen bond with OQ of Ser-18 (distance = 3.0
Aî ) and four other residues have atoms within 5.0 Aî from His-
48-Nd, blocking access to this atom. In this context, the modi-
¢ed histidine either provokes a steric hindrance in the active
site of the closed form or more probably prevents the forma-
tion of the closed conformation after its modi¢cation in the
open state. Hence, enzyme inactivation upon modi¢cation
points to an involvement of the closed conformation in the
catalytic pathway of VL. A catalytic role for His-137 is ruled
out as no substantial decrease in activity is observed after its
mutation to Asn.
In the closed conformation, the narrowest opening at the
active site entrance is reduced to approximately 2.5 Aî which is
too small to allow the peptidoglycan substrate to enter the
active site cleft. The open conformation is thus certainly in-
volved in the catalytic pathway, at least for substrate binding.
Therefore, as both conformations appear to play a role in the
mechanism of action of VL, the large conformational change
observed in the crystal structure is most likely an important
functional feature.
In the case of T4L, the hinge-bending motion opens the
active site cleft in the absence of substrate, and closes it
upon substrate binding [8]. This active site closing was de-
scribed as an intrinsic property of T4L but there was no ex-
perimental evidence for a critical role for this motion.
Although the nature of the conformational change observed
for VL is di¡erent, a similar functional property may be ex-
pected as the proteins are evolutionarily related. Hence, our
results support this hypothesis and suggest that closing the
Fig. 2. Ribbon diagram illustrating the open (right) and closed (left) conformations observed in the three-dimensional structure of VL (Protein
Data Bank code 1am7 [6]). The three histidines and the essential glutamic acid (Glu-19) are represented in ball and stick mode. Only His-137
undergoes a large spatial movement upon changing from one conformation to the other.
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active site upon substrate binding is a general essential feature
of viral lysozymes.
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